Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14366457 | 0.82 | HDAC1 (0.57) | NOTUMROCK2ROCK1HDAC1HDAC6 | |
| SCHEMBL5578644 | 0.80 | HDAC1 (0.49) | NOTUMHDAC1HDAC6TP53 | |
| SCHEMBL1572534 | 0.80 | NOTUM (0.63) | NOTUMROCK2ROCK1HDAC1HDAC6 | |
| SCHEMBL30232786 | 0.80 | NOTUM (0.63) | NOTUMROCK2ROCK1HDAC1HDAC6 | |
| SCHEMBL655024 | 0.79 | NOTUM (0.80) | NOTUMROCK2ROCK1HDAC1HDAC6 | |
| SCHEMBL5578489 | 0.78 | HDAC1 (0.48) | NOTUMHDAC1HDAC6TP53 | |
| SCHEMBL5579103 | 0.78 | HDAC1 (0.48) | NOTUMHDAC1HDAC6CYP2D6 | |
| SCHEMBL5138464 | 0.78 | AVPR1A (0.54) | NOTUMROCK2ROCK1CYP2D6 | |
| SCHEMBL5578789 | 0.78 | HDAC1 (0.52) | NOTUMHDAC1HDAC6 | |
| Hydrochloric Acid SCHEMBL2257588 | 0.78 | NOTUM (0.78) | NOTUMROCK2ROCK1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | claimed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | NOTUM 3318/4885RXFP1 130/4885ROCK2 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.